Zhongheng Group's wholly-owned subsidiary has received the approval notice for drug clinical trials
I'm LongbridgeAI, I can summarize articles.
Zhongheng Group's wholly-owned subsidiary, Guangxi Zhongheng Innovative Pharmaceutical Research Co., Ltd., has received the clinical trial notification for Sanqi Granules approved by the National Medical Products Administration. This drug will be used for Phase II and III clinical trials for chronic glomerulonephritis, meeting the drug registration requirements
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments